WO2026038156 - NOVEL CRYSTALLINE FORMS
National phase entry is expected:
Publication Number
WO/2026/038156
Publication Date
19.02.2026
International Application No.
PCT/IB2025/058227
International Filing Date
13.08.2025
Title **
[English]
NOVEL CRYSTALLINE FORMS
[French]
NOUVELLES FORMES CRISTALLINES
Applicants **
ASSEMBLY BIOSCIENCES, INC.
Inventors
ZONG, Zhixin
WU, Yi
JOHNSON, Mark
Priority Data
63/683,499
15.08.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3052 | |
| EPO | Filing, Examination, Granting | 14161 | |
| Japan | Filing, Examination, Granting | 2329 | |
| South Korea | Filing, Examination, Granting | 2359 | |
| USA | Filing, Examination, Granting | 6390 |
Total:
28,291
Contact Us
Abstract[English]
The invention relates to novel crystalline forms of a compound, as well as to pharmaceutical compositions comprising the same, methods for their production, the use of the crystalline forms in medicaments and for the treatment of diseases or disorders caused by, or associated with hepatitis B virus (HBV) and/or hepatitis D virus (HDV). Compound (1)[French]
L'invention concerne de nouvelles formes cristallines d'un composé, ainsi que des compositions pharmaceutiques les comprenant, des procédés pour leur production, l'utilisation des formes cristallines dans des médicaments et pour le traitement de maladies ou de troubles provoqués par, ou associés au virus de l'hépatite B (VHB) et/ou au virus de l'hépatite D (VHD). Composé (1)